Erectile Dysfunction Market: High prevalence of ED disorders is anticipated to increase at pace in the forecast period

The research report by DataM Intelligence titled ‘Global Erectile Dysfunction Market – Size, Share and Forecast (2019-2026)’ analyses the scope and trends prevailing in this industry.

Erectile Dysfunction Market - Epidemiology Analysis
The condition is highly prevalent in men above 40 years. According to WHO, ED is a common male sexual health problem affecting men of all ages, especially the middle-aged men. Globally, over 150 million men worldwide were estimated to have been affected by ED in 1995, and this is projected to rise to 320 million by 2025, an increase of nearly 170 million men. Though the condition is highly prevalent, it is considered as one of the most underdiagnosed and undertreated conditions.

Erectile Dysfunction Market Dynamics
Studies have demonstrated that over 80% of ED cases are caused by other co-morbid conditions including diseases such as benign prostate hyperplasia, diabetes, high blood pressure, and high cholesterol. The prevalence of the most chronic disease is increasing in both developing and developed countries, thus increasing the prevalence of ED. According to the International Diabetes Federation, the global prevalence of diabetes is set to reach 642 million by 2040 from around 415 million in 2015.
Advances in medical markedly widened the options for the treatment and management of ED. The One-touch release (OTR) touch pads allows easy and one-handed deflation. Overall, the increase in preferability of technologically advanced devices with improved features can boost the market growth in the forecast period.
Low-treatment seeking pool (especially in developing countries), generic erosion of blockbuster ED drugs such as Viagra, Cialis and Levitra are major factors restraining the market growth.

Get a free sample of the research report - https://www.datamintelligence.com/research-report/erectile-dysfunction-market

Erectile Dysfunction Market Segmentation Analysis
Based on therapy type, the market is broadly segmented as the global erectile dysfunction drug therapy and global erectile dysfunction device therapy. The drug therapy accounted for more than 80% of the market in 2018 and is anticipated to retain its global dominance by the end of the forecast period, despite significant generic erosion. The device therapy is anticipated to increase sustainably in the near future.
The ED drug therapy market further segmented as oral therapies, topical therapies, and intraurethral suppositories and penile injection therapies. Oral therapies accounted for the predominant market share in 2018. Oral therapies are mainly comprised of PDE5 inhibitor drugs. The market value for oral PDE5 inhibitors is anticipated to decrease notably especially due to the market entry of generic versions of key oral drugs Viagra, Cialis and Levitra. The market for other drug therapy types, topical agents, intraurethral suppositories and intracavernosal injections, is anticipated to grow at a marginal rate. Increase in product uptake novel topical agent such as – Vitaros, increase in preferability of needle-free penile injection kits, increase in disease awareness are anticipated to boost the market growth of non-oral therapies in the forecast period.

Global Erectile Dysfunction Market Geographical Share
The global ED market is segmented into North America, Europe, Asia Pacific, South America, and Middle East & Africa. The global market for ED is anticipated to witness a negative growth in the forecast period owing to patent expiry of key ED drugs Viagra, Cialis and Levitra. North America holds the major market share. It accounted for more than 45% of the market in 2018. Large disease population coupled with better access to ED treatments, high reimbursement coverage for high post penile implant surgeries in the US are few of the key factors for its high market share. The market value for ED is anticipated to fall significantly in the region owing to the loss of patent exclusivity of ED drugs.
APAC accounts for the third largest share of the global market. Low treatment-seeking rates, high associated social stigma in selected regions, low disease awareness and comparatively low access to healthcare services especially in developing countries are few factors limiting the market growth in the region. However, the market is anticipated to grow at a moderate pace in the forecast period. High disease prevalence population, rise in healthcare spending, increase in ED awareness, increase in uptake of ED drugs will boost ED market growth in this region.

Global Erectile Dysfunction Market Competitive Trends
The market for is ED drugs is oligopolistic, as a limited number of players account for the predominant market share. The ED drugs segment is dominated by key global players such as Pfizer, Eli Lilly, and Bayer. The two companies which occupy the major share of the ED devices segment include Coloplast and Boston Scientific.
The competitive landscape of both ED drugs and devices is highly dynamic with robust strategic activities. The ED drug manufacturers are highly focused on enhancing geographical outreach by the formation of agreements with local vendors in various regions.

To know more about the report - https://www.datamintelligence.com/research-report/erectile-dysfunction-market

This report contains the following table of contents
1. Erectile Dysfunction Market – Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Erectile Dysfunction Market – Market Definition and Overview
3. Erectile Dysfunction Market – Executive Summary
3.1. Market Snippet by Type
3.2. Market Snippet by End User
3.3. Market Snippet by Region
4. Erectile Dysfunction Market Dynamics
4.1. Market Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Incidence of Erectile Dysfunction
4.1.1.2. Rise in Disease Awareness and Diagnosed Population
4.1.1.3. Advent of Novel and Customized Treatment Devices
4.1.2. Restraints
4.1.2.1. Patent Expiry of Major Drugs
4.1.2.2. Low Treatment-Seeking Pool in Developing Countries
4.1.2.3. Restraint 3
4.1.3. Opportunities
4.1.4. Impact Analysis
5. Erectile Dysfunction Market – Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Regulatory Analysis
5.3. Epidemiology Analysis
5.4. Unmet Needs Analysis
6. Erectile Dysfunction Market – Pipeline Landscape
6.1. Pipeline Overview
6.2. Key Pipeline Drugs & Devices
7. Erectile Dysfunction Market – By Therapy Type
7.1. Drug Therapy
7.2. Topical Therapy
7.2. Oral Therapy
7.3. Others (Injectables & Suppositories)
7.4. Device Therapy
7.5. Penile Implants
7.6. Vacuum Therapy Devices
7.7. Others
8. Erectile Dysfunction Market – By Region
8.1. Introduction
8.2. North America
8.2.1. The U.S.
8.2.2. Canada
8.2.3. Mexico
8.3. Europe
8.3.1. Germany
8.3.2. The U.K.
8.3.3. France
8.3.4. Italy
8.3.5. Spain
8.3.6. Rest of Europe
8.4. South America
8.4.1. Brazil
8.4.2. Argentina
8.4.3. Rest of South America
8.5. Asia Pacific
8.5.1. China
8.5.2. India
8.5.3. Japan
8.5.4. Australia
8.5.5. Rest of Asia Pacific
8.6. Middle East & Africa
9. Erectile Dysfunction Market – Competitive Landscape
9.1. Competitive Scenario
9.2. Competitor Erectile Dysfunction Strategy Analysis
9.3. Comparative Product Portfolio Analysis
9.4. Market Positioning/Share Analysis
9.5. Mergers and Acquisitions Analysis
10. Erectile Dysfunction Market – Company Profiles
10.1. Bayer Inc
10.2. Eli Lilly and Company
10.3. Pfizer Inc.
10.4. VIVUS, Inc
10.5. Coloplast A/S
10.6. Boston Scientific
10.7. Endo International
10.8. Apricus Biosciences
10.9. Teva Pharmaceuticals
10.10. Dong-A Pharma
10.11. Future Medical
10.12. Augusta Medical Systems LLC
10.13. Promedon
10.14. Zephyr Surgical Implants
11. Erectile Dysfunction Market – Premium Insights
12. Erectile Dysfunction Market – DataM
12.1. Appendix
12.2. About Us and Services
12.3. Contact Us

About DataM Intelligence

DataM Intelligence 4Market Research is a Market Intelligence and Business Research firm, based in India. It aims to bridge the two main aspects of a business decision - opinion and supportive data.

DMI is currently strengthening its cross-industrial database for sectors including Chemicals, Materials, Agriculture, Healthcare Services, Animal Nutrition, Consumer Goods, Food & Beverages, Industrial Machinery and Automation among others.

Corporate Address
1st floor, Phoenix Tech Tower, Plot no: 14/46, Habsidguda, IDA-Uppal, Hyderabad-500039, Telangana

Email
info@datamintelligence.com

Phone
+1 877-441-4866

This release was published on openPR.